AGL 38.31 Decreased By ▼ -0.52 (-1.34%)
AIRLINK 141.40 Decreased By ▼ -2.00 (-1.39%)
BOP 5.64 Increased By ▲ 0.40 (7.63%)
CNERGY 3.87 Increased By ▲ 0.15 (4.03%)
DCL 7.56 Decreased By ▼ -0.02 (-0.26%)
DFML 47.40 Increased By ▲ 1.00 (2.16%)
DGKC 79.75 Decreased By ▼ -1.13 (-1.4%)
FCCL 27.44 Increased By ▲ 0.02 (0.07%)
FFBL 54.85 Decreased By ▼ -0.15 (-0.27%)
FFL 8.60 Increased By ▲ 0.04 (0.47%)
HUBC 113.51 Increased By ▲ 2.49 (2.24%)
HUMNL 11.20 Decreased By ▼ -0.22 (-1.93%)
KEL 3.99 Increased By ▲ 0.22 (5.84%)
KOSM 8.54 Increased By ▲ 0.21 (2.52%)
MLCF 35.00 Decreased By ▼ -0.20 (-0.57%)
NBP 63.80 Increased By ▲ 2.45 (3.99%)
OGDC 169.40 Decreased By ▼ -2.50 (-1.45%)
PAEL 25.18 Decreased By ▼ -0.60 (-2.33%)
PIBTL 5.89 Decreased By ▼ -0.08 (-1.34%)
PPL 125.75 Decreased By ▼ -1.80 (-1.41%)
PRL 24.79 Decreased By ▼ -0.79 (-3.09%)
PTC 13.26 Increased By ▲ 1.11 (9.14%)
SEARL 57.45 Increased By ▲ 0.45 (0.79%)
TELE 7.12 Increased By ▲ 0.02 (0.28%)
TOMCL 35.00 Increased By ▲ 0.20 (0.57%)
TPLP 7.45 Increased By ▲ 0.50 (7.19%)
TREET 14.32 Increased By ▲ 0.47 (3.39%)
TRG 46.54 Decreased By ▼ -0.51 (-1.08%)
UNITY 26.18 Increased By ▲ 0.13 (0.5%)
WTL 1.20 Decreased By ▼ -0.01 (-0.83%)
BR100 9,091 Decreased By -2.4 (-0.03%)
BR30 27,347 Increased By 28.9 (0.11%)
KSE100 85,669 Increased By 5.3 (0.01%)
KSE30 27,216 Decreased By -224.9 (-0.82%)

Pakistan’s pharmaceutical company BF Biosciences Limited (BFBL) has successfully launched a human insulin under the brand name ‘Ferulin’.

The development was shared by Ferozsons Laboratories Limited, the parent company of BFBL, in its notice to the Pakistan Stock Exchange (PSX) on Thursday.

“We are pleased to inform you that BF Biosciences Limited, a subsidiary of Ferozsons Laboratories Limited, has successfully launched human insulin under the brand name ‘Ferulin’,” read the notice.

It is pertinent to inform that human insulin is a synthetic form of insulin that is identical to the insulin produced naturally by the human pancreas. Insulin is a hormone that plays a crucial role in managing blood glucose levels, especially for people with diabetes.

Meanwhile, the company in its statement said the launch marks a significant milestone in its commitment to stop diabetes, expand the product portfolio and enhance the availability of life-saving medicines in the market.

“Ferulin has been developed with the highest quality standards and is intended to provide effective and affordable diabetes treatment to patients across Pakistan,” the company claimed.

“We are confident that Ferulin will positively impact our subsidiary’s growth and will further strengthen our mission to address unmet patient needs,” it added.

BFBL, a joint venture between Ferozsons Laboratories Limited and Argentina’s Bagó Group, specialises in the import, manufacturing, marketing, and distribution of pharmaceutical products.

The company is planning an initial public offering (IPO) at the PSX, aiming to raise at least Rs1.375 billion ($4.94 million) by issuing 25 million shares at a floor price of Rs55 per share.

The company is a pioneer in local manufacturing of hepatitis related medicines (i.e. interferon injections).

In 2020, BFBL executed a non-exclusive license agreement with Gilead Sciences, Inc. for the manufacture and sale of Remdesivir (an anti-viral drug for the treatment of COVID-19 patients) under Gilead’s Global Patient Solutions (GPS) Program.

BFBL successfully produced Remdesivir during the COVID-19 pandemic, contributing approximately Rs2 billion to its topline in FY2021-FY2022.

Comments

200 characters
[email protected] Aug 16, 2024 03:04pm
Good
thumb_up Recommended (0) reply Reply
nadeem Baig Aug 16, 2024 05:03pm
There good news local manufacturing in Pakistan. what price in Pakistan . does better from International insulin.nadeemiqbal. please send more information in my Gmail
thumb_up Recommended (0) reply Reply
nadeem Baig Aug 16, 2024 05:03pm
send more than information in my Gmail
thumb_up Recommended (0) reply Reply